WESTWOOD, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Corza Medical
(https://corza.com/) successfully closed its previously announced acquisition of
the TachoSil manufacturing operations in Linz, Austria, part of Takeda's global
production network. TachoSil (https://corza.com/products/tachosil/) is a best-
in-class surgical patch trusted by medical professionals across the globe.
Corza Medical acquired the commercial rights for TachoSil in January 2021
(https://corza.com/gtcr-and-gregory-t-lucier-announce-merger-of-surgical-
specialties-and-tachosil-to-create-corza-medical/). The acquisition of the
manufacturing operations will enable Corza Medical to further deliver
exceptional value to its customers by combining operational excellence with its
commercial excellence engine. It will also allow the company to control
manufacturing priorities directly, accelerating enhanced service levels and
support to customers globally.
"The acquisition of TachoSil manufacturing operations marks a significant
milestone for Corza Medical. We are excited to have completed the acquisition
successfully and welcome the employees transferring from Takeda," said Tom Testa
(https://www.linkedin.com/in/tbtesta/), CEO of Corza Medical. "This acquisition
will enable us to enhance our product offerings and better serve our customers.
We are committed to investing in TachoSil to improve patient care and deliver
innovative solutions to surgeons worldwide."
Executive Chairman Gregory T. Lucier (https://www.linkedin.com/in/greglucier/)
of Corza Medical added, "The investment to own the TachoSil manufacturing
operations in Linz will help streamline the supply chain and build a stronger
operational capability for our Biosurgery business. We are confident that with
the Linz facilities as part of our operations, we will enhance the support for
our customers and further deliver on Corza's brand promise of remarkable
service, trusted performance, and outstanding value to meet the needs of
healthcare professionals."
"By taking ownership of the entire manufacturing process, we will be able to
accelerate our growth by increasing our manufacturing capacity and serving new
countries. We are excited to advance patient care everywhere in the world," said
Thierry Leclercq (https://www.linkedin.com/in/thierry-leclercq-589699135/) Corza
Medical's SVP, GM Biosurgery.
Corza Medical is a portfolio company of GTCR, a leading private equity firm,
which helped create and build the business in partnership with Gregory T.
Lucier. With a focused commitment to remarkable service, trusted performance,
and outstanding economic value to customers, Corza Medical has the experience
and resources to continue investing in TachoSil for the benefit of its surgeons,
partners, and patients around the world.
About Corza Medical
Corza Medical is a leading global manufacturer of innovative surgical
technologies. With a global team of over 3,000 employees supporting clinicians,
distributor-partners, and medical device companies worldwide, Corza provides
healthcare professionals a platform of surgical technologies with many industry-
leading brands, including Quill(®) barbed sutures, Sharpoint(®) Plus and Look(TM)
surgical sutures, Katena(®) reusable and Blink(TM) single-use ophthalmic
instruments, Barron corneal transplant devices, Sharpoint(®) microsurgical
knives, and the TachoSil(®) fibrin sealant patch. For more information, please
visit www.corza.com (http://www.corza.com/).
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The
Leaders Strategy(TM) - finding and partnering with management leaders in core
domains to identify, acquire and build market-leading companies through organic
growth and strategic acquisitions. GTCR is focused on investing in
transformative growth in companies in the Business & Consumer Services,
Financial Services & Technology, Healthcare and Technology, Media &
Telecommunications sectors. Since its inception, GTCR has invested more than $25
billion in over 270 companies, and the firm currently manages more than $40
billion in equity capital. GTCR is based in Chicago with offices in New York and
West Palm Beach. For more information, please visit www.gtcr.com
(https://www.gtcr.com/). Follow us on LinkedIn
(https://www.linkedin.com/company/gtcr-llc/).
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3b1335ed-d9ff-
41b3-8bfa-81535087cd22
Â